Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the main cause of de...

Full description

Bibliographic Details
Main Authors: Genlong Xue, Xiaolei Yang, Ge Zhan, Xin Wang, Jinghan Gao, Yong Zhao, Xinying Wang, Jiatian Li, Zhenwei Pan, Yunlong Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
sodium–glucose cotransporter 2
empagliflozin
myocardial infarction
membrane potential
intracellular Ca2+
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.988408/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.988408/full

Similar Items